Evaluating Myelodysplastic Syndrome Risks in NET Patients Planned for Peptide Radionuclide Therapy

NCT06510868 · clinicaltrials.gov ↗

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions

RADIATION: Peptide receptor radionuclide therapy (PRRT)
DIAGNOSTIC_TEST: Blood collection

Sponsor

University Health Network, Toronto